Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease

NCT05456932 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-03-31

No results posted yet for this study

Summary

Iron deficiency anemia is the most common systemic manifestation of Inflammatory Bowel Diseases (IBD)-Crohn's disease and ulcerative colitis. Iron deficiency with or without anemia poses a diagnostic and therapeutic challenge due to chronic gastrointestinal blood loss and the inflammatory nature of IBD. Recent illumination of iron metabolism has brought attention to the systemic iron regulator-hepcidin, a peptide hormone that regulates intestinal iron absorption and systemic iron availability. Elevated hepcidin is associated with oral iron malabsorption in IBD. This study aims to evaluate whether hepcidin concentration at baseline can predict response to oral and intravenous iron therapy in patients with IBD and concomitant iron deficiency with or without anemia.

Conditions

Interventions

DRUG

Intravenous iron

Included participants will receive intravenous iron therapy, the dosage will be based on national pharmaceutical formulary.

DRUG

Ferric maltol

Included participants will receive oral iron therapy with ferric maltol (twice a day 30mg for 12 weeks)

DRUG

Ferrous fumarate

Included participants will receive oral iron therapy with ferrous fumarate (twice a day 100mg for 12 weeks)

Sponsors & Collaborators

  • University Medical Center Groningen

    collaborator OTHER
  • Radboud University Medical Center

    collaborator OTHER
  • Maastricht University Medical Center

    collaborator OTHER
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER
  • Leiden University Medical Center

    lead OTHER

Principal Investigators

  • A.E. van der Meulen - de Jong, MD, PhD · LUMC

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-19
Primary Completion
2023-08-31
Completion
2023-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05456932 on ClinicalTrials.gov